Shattuck Labs (STTK) Income from Continuing Operations (2019 - 2026)
Shattuck Labs' (STTK) quarterly Income from Continuing Operations came in at 14766000.0 in Q1 2026, down 7.78% year-on-year from 16011888.55 in Q1 2025, and up 87.7% on a QoQ basis from 120057000.0 in Q4 2025.
Shattuck Labs (STTK) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 8 years of Income from Continuing Operations data on file, last reported at 14766000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 7.78% year-over-year to 14766000.0 in Q1 2026; TTM through Mar 2026 was 159071000.0, a 7.49% increase from a year earlier, with the FY2025 full-year figure at 155491000.0, up 9.08% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 14766000.0, up from 120057000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for STTK reached as high as 11116000.0 in Q3 2025 and fell as low as 120057000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 38259235.29 across 5 years, with a median of 26076000.0 in 2022.
- Across the five-year window, Income from Continuing Operations tumbled 265.61% in 2023 and soared 57.77% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 26076000.0 in 2022, then tumbled by 265.61% to 95337000.0 in 2023, then fell by 20.9% to 115263000.0 in 2024, then retreated by 4.16% to 120057000.0 in 2025, then surged by 87.7% to 14766000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 14766000.0 in Q1 2026, 120057000.0 in Q4 2025, and 11116000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Shattuck Labs | 831.66 Mn | 831.66 Mn | - | -14.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.77 Mn |
| Dec 31, 2025 | -120.06 Mn |
| Sep 30, 2025 | -11.12 Mn |
| Jun 30, 2025 | -13.13 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -115.26 Mn |
| Sep 30, 2024 | -18.72 Mn |
| Jun 30, 2024 | -24.26 Mn |
| Mar 31, 2024 | -32.44 Mn |
| Dec 31, 2023 | -95.34 Mn |
| Sep 30, 2023 | -28.70 Mn |
| Jun 30, 2023 | -23.05 Mn |
| Mar 31, 2023 | -21.86 Mn |
| Dec 31, 2022 | -26.08 Mn |
| Sep 30, 2022 | -31.67 Mn |
| Jun 30, 2022 | -29.15 Mn |
| Mar 31, 2022 | -31.11 Mn |
| Dec 31, 2021 | -22.41 Mn |
| Sep 30, 2021 | -36.63 Mn |
| Jun 30, 2021 | -49.51 Mn |